National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, raised $625 million in a Series D financing, in addition to a previously unannounced $600 million Series C financing completed in August 2021.
 
The company will use the funding to continue to invest in building its infrastructure network through strategic collaborations, acquisitions, organic growth and international expansion, and by developing innovative biomanufacturing technologies. Resilience is also investing in advanced R&D, including stable cell lines for viral vector production, distributed manufacturing for autologous cell therapy and cell-free and continuous manufacturing for biologics.
 
“We have an ambitious goal to reinvent biomanufacturing by bringing new processes and technologies to an industry that hasn’t kept pace with the explosive innovation in drug discovery,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. “While we recognize that our goal is neither quick nor easy, we are driven by our mission to democratize access to medicines. These new funds will help support our next phase of growth, as we continue to innovate biomanufacturing across all our modalities, expand our footprint to serve customers, sign strategic collaborations and support the developers of a new generation of complex medicines.”
 
Resilience, which focuses on five therapeutic modalities – biologics, vaccines, nucleic acids and cell and gene therapies – currently has 10 facilities across North America, with more than 1 million square feet of manufacturing space and more than 1,600 employees. The company’s network, which is expected to add capacity and capabilities this year with projects underway at several existing sites, scales customer projects from process and analytical development through preclinical to large scale commercial drug substance and drug product manufacturing.
 
Resilience’s business model enables it to partner with customers across therapeutic modalities, through fee-for-service arrangements, value-share agreements and new company creation/incubation projects. The company also provides opportunities for early access and out licensing of next-generation technologies.